Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma

Cell Cycle

Volumn 11, Issue 6, 2012, Pages 1076-1080

  Oricchio, Elisa ^a   Wendel, Hans Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

EPHA7; Genomic data; Lymphoma; Tumor suppressor

Indexed keywords

COMPLEMENTARY DNA; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A3; EPHRIN RECEPTOR A7; MICRORNA; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RITUXIMAB; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; B LYMPHOCYTE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CARCINOMA IN SITU; CELL CYCLE; CELL DEATH; CELL LINE; CHROMOSOME; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENETIC CODE; GENETIC SCREENING; GENOME; GENOMIC IN SITU HYBRIDIZATION; HUMAN; IN VIVO STUDY; LYMPHOMA; METHYLATION; NONHODGKIN LYMPHOMA; PHENOTYPE; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

EID: 84858726237     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.6.19451     Document Type: Review

References (39)

1. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 2011; 147:554-64; PMID:22036564; http://dx.doi.org/10.1016/j.cell.2011.09. 035.
2. Oricchio E, Wolfe AL, Schatz JH, Mavrakis KJ, Wendel HG. Mouse models of cancer as biological filters for complex genomic data. Dis Model Mech 2010; 3:701-4; PMID:20876355; http://dx.doi.org/10.1242/dmm.006296.
3. Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007; 21:18-29; PMID:17039231; http://dx.doi.org/10.1038/sj. leu.2404426.
4. Staudt LM, Wilson WH. Focus on lymphomas. Cancer Cell 2002; 2:363-6; PMID:12450791; http://dx.doi.org/10.1016/S1535-6108(02)00178-2.
5. Gaidano G, Hauptschein RS, Parsa NZ, Offit K, Rao PH, Lenoir G, et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood 1992; 80:1781-7; PMID:1356511.
6. Offit K, Parsa NZ, Gaidano G, Filippa DA, Louie D, Pan D, et al. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin lymphoma. Blood 1993; 82:2157-62; PMID:8104536.
7. Nanjangud G, Rao PH, Teruya-Feldstein J, Donnelly G, Qin J, Mehra S, et al. Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression. Cytogenet Genome Res 2007; 118:337-44; PMID:18000388; http://dx.doi.org/10.1159/ 000108318.
8. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298-303; PMID:21796119; http://dx.doi.org/10.1038/nature10351.
9. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42:181-5; PMID:20081860; http://dx.doi.org/10.1038/ng.518.
10. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418:38-9; PMID:12097900; http://dx.doi.org/10.1038/418038a.
11. Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005; 37:1289-95; PMID:16200064.
12. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125:1253-67; PMID:16814713; http://dx.doi.org/10.1016/j.cell.2006.05.030.
13. Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319:620-4; PMID:18239126; http://dx.doi.org/10.1126/science.1149200.
14. Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008; 319:617-20; PMID:18239125; http://dx.doi.org/10.1126/science. 1149185.
15. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 2008; 135:852-64; PMID:19012953; http://dx.doi.org/10.1016/j.cell. 2008.09.061.
16. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16:324-35; PMID:19800577; http://dx.doi.org/10.1016/j.ccr.2009.08.015.
17. Egle A, Harris AW, Bath ML, O'Reilly L, Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004; 103:2276-83; PMID:14630790; http://dx.doi.org/10.1182/blood-2003-07-2469.
18. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell 2008; 133:38-52; PMID:18394988; http://dx.doi.org/10.1016/j.cell. 2008.03.011.
19. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10:165-80; PMID:20179713; http://dx.doi.org/10.1038/nrc2806.
20. Depaepe V, Suarez-Gonzalez N, Dufour A, Passante L, Gorski JA, Jones KR, et al. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 2005; 435:1244-50; PMID:15902206; http://dx.doi.org/10.1038/ nature03651.
21. Nie D, Di Nardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, et al. Tsc2-Rheb signaling regulates EphA-mediated axon guidance. Nat Neurosci 2010; 13:163-72; PMID:20062052; http://dx.doi.org/10.1038/nn.2477.
22. Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature 2010; 465:487-91; PMID:20445540; http://dx.doi.org/10.1038/ nature08995.
23. Holmberg J, Clarke DL, Frisén J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 2000; 408:203-6; PMID:11089974; http://dx.doi.org/10.1038/35041577.
24. Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 2007; 26:4243-52; PMID:17260020; http://dx.doi.org/10.1038/sj.onc.1210211.
25. Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H, Tong W, et al. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 2010; 115:2412-9; PMID:20061560; http://dx.doi.org/10.1182/blood-2009-05-222208.
26. Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene 2005; 24:5637-47; PMID:16007213; http://dx.doi.org/10.1038/sj.onc.1208720.
27. Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer 2009; 124:88-94; PMID:18821581; http://dx.doi.org/10.1002/ijc.23890.
28. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-75; PMID:18948947; http://dx.doi.org/10.1038/nature07423.
29. Lisabeth EM, Fernandez C, Pasquale EB. Cancer Somatic Mutations Disrupt Functions of the EphA3 Receptor Tyrosine Kinase Through Multiple Mechanisms. Biochemistry 2012; PMID:22242939; http://dx.doi.org/10.1021/bi2014079.
30. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001; 61:2301-6; PMID:11280802.
31. Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008; 7:1098-103; PMID:18443431; http://dx.doi.org/10.4161/cbt.7.7.6168.
32. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60; PMID:17251933; http://dx.doi.org/10. 1038/nature05529.
33. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445:661-5; PMID:17251932; http://dx.doi.org/10.1038/nature05541.
34. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002; 297:63-4; PMID:12098689; http://dx.doi.org/10.1126/ science.1073096.
35. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21:3214-31; PMID:18079171; http://dx.doi.org/10.1101/gad.1609907.
36. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459:712-6; PMID:19412163; http://dx.doi.org/10.1038/nature07969.
37. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 2009; 459:717-21; PMID:19412164; http://dx.doi.org/10. 1038/nature07968.
38. Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell 2010; 18:568-79; PMID:21156281; http://dx.doi.org/10.1016/j.ccr.2010.10.030.
39. De S, Michor F. DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol 2011; 29:1103-8; PMID:22101487; http://dx.doi.org/10.1038/nbt.2030.